What amount sold does Magnesium Development Company, LLC report in Form D filings?

The latest linked filings report $2.5M sold across 1 identified offering(s). 0 unlinked amendment(s) are excluded; 0 offering(s) have no reported amount sold. This is not verified lifetime funding or money raised during a specific period.

When was Magnesium Development Company, LLC's most recent SEC filing?

Magnesium Development Company, LLC's most recent Form D filing was on 2019-02-19.

How many investors does Magnesium Development Company, LLC have?

The most recent Form D filing lists 9 investor(s).

What type of securities does Magnesium Development Company, LLC offer?

Magnesium Development Company, LLC's SEC Form D filings indicate equity offerings.

Magnesium Development Company, LLC

CIK: 0001666465·Biotechnology·HOLLAND, MI·Limited Liability Company·Founded 2014

Reported Sold

$2,450,000

Total Filings

Identified Offerings

Last Filed

Feb 19, 2019

Employees

—

Reported sold uses the latest linked filing for each identified offering; it is not verified lifetime funding. SPV filings are shown separately.

About

Company in Biotechnology industry

SEC EDGAR

Offering filing timeline

Feb 19, 2019Form D/A — Amendment

Reported sold: $2,450,000 · Target: $2,450,000

Rule 506(b)·9 investors

Changed: Reported amount sold, Offering target, Reported investors

Sep 26, 2017Form D/A — Amendment

Reported sold: $1,800,000 · Target: $1,800,000

Rule 506(b)·5 investors

Changed: Reported amount sold, Offering target, Reported investors, Reported revenue range

Feb 16, 2016Form D — New notice

Reported sold: $1,000,000 · Target: $1,000,000

Rule 506(b)·4 investors

Fundraising Profile

Exemptions

Rule 506(b)

Investors in latest filing

Revenue Range

Decline to Disclose

Reported commissions across identified offerings

Amendment Rate

67%

Latest reported sold across 1 identified offering

$2,450,000

Uses the latest linked filing for each offering. This is not a measure of money raised in the last year or verified lifetime funding.

Key People

Matthew Ahearn

Related Person

Appears on 3 filings

Donald Running

Related Person

Appears on 3 filings

Jeff Ondrla

Related Person

Appears on 3 filings

Stephen LeBeau

Related Person

Appears on 3 filings

Matt Milanowksi

Related Person

Appears on 2 filings

Michael DeVries

Related Person

Appears on 2 filings

Robert Ball

Related Person

Appears on 2 filings

Mike DeVries

Related Person

Appears on 1 filing

Filing History

Date	Type	Offering target	Reported sold	Investors
Feb 19, 2019	Amendment	$2,450,000	$2,450,000	9
Sep 26, 2017	Amendment	$1,800,000	$1,800,000	5
Feb 16, 2016	New	$1,000,000	$1,000,000	4

Filing History

Amendment insights

Loading amendment history…

Comparable issuers

Matched on reported industry and issuer type, then ranked by business location, offering target, and recency. These are filing comparables, not verified business competitors.

Dvant Pharma, Inc.

Biotechnology

Offering target: $3,090,400

Filed Oct 13, 2026